Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Last Close
Dec 05 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-6.37 Insider Own7.13% Shs Outstand21.06M Perf Week-2.47%
Market Cap199.44M Forward P/E- EPS next Y-4.39 Insider Trans0.00% Shs Float19.56M Perf Month1.07%
Income-133.82M PEG- EPS next Q-1.20 Inst Own96.66% Short Float / Ratio7.70% / 3.24 Perf Quarter-21.93%
Sales79.20M P/S2.52 EPS this Y27.09% Inst Trans-2.80% Short Interest1.51M Perf Half Y-63.38%
Book/sh10.29 P/B0.92 EPS next Y5.54% ROA-31.47% Target Price23.00 Perf Year-79.07%
Cash/sh17.56 P/C0.54 EPS next 5Y- ROE-49.74% 52W Range8.08 - 62.06 Perf YTD-79.64%
Dividend- P/FCF- EPS past 5Y- ROI-33.55% 52W High-84.74% Beta0.46
Dividend %- Quick Ratio6.73 Sales past 5Y-16.21% Gross Margin97.01% 52W Low17.20% ATR0.66
Employees145 Current Ratio6.73 Sales Q/Q-6.82% Oper. Margin-173.23% RSI (14)50.10 Volatility6.63% 7.06%
OptionableYes Debt/Eq1.03 EPS Q/Q-5.14% Profit Margin-168.95% Rel Volume0.53 Prev Close10.00
ShortableYes LT Debt/Eq0.84 EarningsNov 20 AMC Payout- Avg Volume464.52K Price9.47
Recom2.50 SMA203.27% SMA50-0.53% SMA200-58.84% Volume247,890 Change-5.30%
Date Action Analyst Rating Change Price Target Change
Aug-09-23Downgrade JP Morgan Neutral → Underweight $14
Aug-08-23Downgrade Jefferies Buy → Hold $49 → $18
Dec-09-22Initiated H.C. Wainwright Buy $56
Jul-06-22Upgrade Evercore ISI In-line → Outperform $62
Jun-01-22Upgrade Evercore ISI Underperform → In-line $39
Oct-07-21Initiated Jefferies Buy $95
Sep-09-21Initiated SVB Leerink Mkt Perform $55
Jan-29-21Upgrade JP Morgan Underweight → Neutral $55
Nov-24-20Initiated Evercore ISI Underperform $30
Aug-28-20Resumed ROTH Capital Buy $104
Nov-27-23 09:55AM
Nov-22-23 07:00AM
Nov-21-23 08:46AM
Nov-20-23 04:54PM
04:18PM Loading…
Nov-16-23 11:22PM
Nov-13-23 10:00AM
Oct-30-23 10:01AM
Oct-13-23 07:00AM
Sep-17-23 12:00PM
Sep-07-23 07:00AM
Sep-01-23 06:51PM
07:00AM Loading…
Aug-31-23 07:00AM
Aug-13-23 08:08AM
Aug-09-23 01:49PM
Aug-08-23 02:23PM
Aug-07-23 05:15PM
Jul-31-23 07:00AM
Jun-21-23 08:00PM
Jun-20-23 07:00AM
Jun-07-23 07:00AM
May-31-23 07:00AM
May-11-23 05:05AM
07:00AM Loading…
May-09-23 07:00AM
May-08-23 05:15PM
May-02-23 04:01PM
Apr-26-23 08:00PM
Apr-25-23 08:01AM
Apr-19-23 09:32AM
Apr-17-23 07:00AM
Apr-06-23 07:00AM
Apr-05-23 07:00AM
Mar-14-23 07:00AM
Mar-08-23 08:51AM
Mar-07-23 07:00AM
Feb-09-23 12:58PM
Feb-08-23 02:13PM
Feb-07-23 05:15PM
Jan-31-23 07:00AM
Jan-06-23 07:00AM
Jan-03-23 07:00AM
Dec-25-22 12:07PM
Nov-23-22 05:09AM
Nov-22-22 07:00AM
Nov-21-22 05:15PM
Nov-14-22 07:00AM
Nov-09-22 07:00AM
Nov-03-22 11:22AM
Oct-19-22 08:00AM
Oct-17-22 07:00AM
Oct-07-22 01:57PM
Oct-03-22 07:00AM
Sep-29-22 07:00AM
Sep-22-22 07:01AM
Sep-07-22 08:30AM
Sep-01-22 07:00AM
Aug-14-22 08:27AM
Aug-11-22 10:55AM
Aug-09-22 12:00AM
Aug-08-22 05:55PM
Aug-02-22 10:00AM
Aug-01-22 07:00AM
Jul-29-22 07:40AM
Jul-28-22 10:03AM
Jul-01-22 09:41AM
Jun-27-22 11:42AM
Jun-24-22 09:03AM
Jun-23-22 10:28AM
Jun-22-22 04:03PM
Jun-21-22 04:50PM
Jun-08-22 07:00AM
Jun-02-22 07:00AM
May-25-22 06:12AM
May-19-22 03:02PM
May-18-22 04:01PM
May-12-22 12:27PM
May-10-22 02:11AM
May-09-22 05:45PM
Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases. The firm also conducts research in human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19). The company was founded by Peter O. Kliem Martin Karplus, James Hogle, Gerard Wagner, Peter M. Howley, and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Gardiner Nathaniel S.Sr. VP & General CounselApr 18Option Exercise30.006,667200,01079,980Apr 19 07:25 PM
Vance TerryDirectorMar 16Option Exercise14.005,80081,20021,095Mar 17 06:46 PM
Or Yat SunSr. VP & CSOMar 15Option Exercise14.0013,925194,950388,627Mar 17 06:37 PM
MELLETT PAUL JTreasurer and CFOMar 15Option Exercise14.0010,440146,160107,996Mar 17 06:41 PM
Or Yat SunSr. VP & CSOMar 15Sale44.4513,925618,960374,702Mar 17 06:37 PM
MELLETT PAUL JTreasurer and CFOMar 15Sale44.4310,440463,80297,556Mar 17 06:41 PM
Luly Jay R.President and CEOMar 13Option Exercise14.0027,912390,768847,722Mar 14 06:26 PM
Luly Jay R.President and CEOMar 13Sale45.1627,9121,260,628819,810Mar 14 06:26 PM
MELLETT PAUL JTreasurer and CFOFeb 09Sale53.765,000268,81683,463Feb 13 07:58 PM
MELLETT PAUL JTreasurer and CFOJan 09Option Exercise14.182,81239,87488,463Jan 10 07:11 PM
Luly Jay R.President and CEODec 19Option Exercise27.5814,500399,910788,305Dec 19 07:50 PM
MELLETT PAUL JTreasurer and CFODec 19Option Exercise14.184,14858,81985,651Dec 19 07:53 PM
Luly Jay R.President and CEODec 16Option Exercise14.1030,000422,907803,805Dec 16 09:44 PM
Luly Jay R.President and CEODec 16Sale44.7230,0001,341,713773,805Dec 16 09:44 PM